Influence of aeroallergen sensitization and nasal polyposis on mepolizumab response in eosinophilic severe asthma

• DOI: 10.2500/aap.2025.46.250003
• Publication Date: 2025-02-27T04:31:02Z
• Authors: Fatma Arzu Akkus; Fatih Colkesen; Tugba Onalan; Recep Evcen; Mehmet Emin Gerek; Mehmet Kilinc; Filiz Sadi Aykan; Sevket Arslan
• Keywords: Aeroallergen

Background: Studies on the impact of comorbidities treatment responses in severe eosinophilic asthma (SEA) are limited. This study was a real-world investigation into how presence or absence nasal polyps (NP) and sensitivity to aeroallergens influence outcomes mepolizumab therapy. Methods: In this retrospective study, data obtained from patients with SEA who received at least 6 months were analyzed. The initially divided two groups based NPs. Within these groups, further categorized subgroups according aeroallergen (AE). Asthma-related resulting four evaluated both before during follow-up period. Results: Among 36 NPs, 14 (38.8%) had AE (NP+AE+), whereas 22 (61.2%) did not (NP+AE‐). Of 35 without 17 (48.5%) (NP‐AE+), 18 (51.5%) (NP‐AE‐). independent AE, significantly associated an increase exacerbations oral corticosteroid (OCS) use (p < 0.001). NP+AE+ group, baseline Asthma Control Test (ACT) score lower, number hospitalizations higher After treatment, all showed significant reductions asthma-related exacerbations, hospitalizations, OCS use. Furthermore, ACT scores pulmonary function test parameters improved. There limited differences improvements among group showing reduction compared other Conclusion: Mepolizumab reduced different phenotypes. Analysis findings suggests that provides benefits regardless NPs AE.